Chylothorax due to tuberculosis lymphadenitis

WOS:000408982500011PubMed ID: 28275756Chylothorax is a rare clinical condition characterized by high triglyceride and low cholesterol levels in milky pleural aspirate. Generally, it occurs through leakage of chyle as result of trauma or malignancy. Chylothorax due to tuberculous lymphadenitis is very rare clinical condition that has only been documented in a few cases. Although precise pathogenesis is not known, enlarged mediastinal and hilar lymph nodes are thought to be associated with opening of collateral anastomosis between thoracic duct and the azygos and intercostal veins by creating pressure on thoracic duct and cisterna chyli. Presently described is case of chylothorax thought to be due to compression from mediastinal tuberculous lymphadenitis, and which had complete remission after antituberculosis treatment

Tracheobronchial amiloidosis

Sistemik tutulum olmadan lokalize pulmoner amiloidozis; nodüler parankimal opasiteler, diffüz parankimal opasiteler veya trakeobronşial amiloidozis (TBA) şeklinde görülebilmektedir. TBA daha ziyade erkeklerde, 5 veya 6. dekatta görülen bir durum olup, trakeobronşial ağaçtaki bening lezyonların %1 kadarıdır. TBA, immun globulin hafif zincirden oluşan amiloid materyelin submukozal plaklar ve/veya polipoid tümorler şeklinde birikimi ile karakterizedir ve ilerleyici hastalık sonucu hava yolu obstrüksiyonuna yol açabilir. Tedavide başlıca lazer eksiyonu olmak üzere tekrarlayan eksizyonel tedaviler açık cerrahiye tercih edilmektedir. Bu yazımızda lokalize TBA tanısı alan bir erkek olgu nadir görülmesi sebebi ile sunuldu.Localized pulmonary amyloidosis without systemic involvement differentiates as nodular parenchymal opacities, diffuse parenchymal opacities, or tracheobronchial amyloidosis (TBA). TBA is a condition mostly seen in males aged up to 50–60 years, accounting for approximately 1% of benign lesions in the tracheobronchial tree. TBA is characterized by the accumulation of the amyloid material comprising immunoglobulin light chain (AL), which are observed as submucosal plaques and/or polypoid tumors; progressive form of tracheobronchial amyloidosis can lead to airway obstruction. Repeated excisional treatments, mainly laser treatment is preferable to open surgery. Here, we have presented the case of a patient diagnosed with the rarely occurring localized TBA

Pulmonary Embolism Originating from a Hepatic Hydatid Cyst Ruptured into the Inferior Vena Cava: CT and MRI Findings

Pulmonary embolism due to hydatid cysts is a very rare clinical entity. Hydatid pulmonary embolism can be distinguished from other causes of pulmonary embolism with contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (MRI). MRI especially displays the cystic nature of lesions better than CECT. Here we report a 45-year-old male patient with the pulmonary embolism due to ruptured hydatid liver cyst into the inferior vena cava

A rare cause of pleural effusion: adult onset Still's disease

Adult onset Stills disease is a rare systemic inflammatory disorder. At the onset of the disease sore throat, pharyngitis; which does not respond to antibiotics, one or two times peaking febrile episodes, marked salmoncolored rash on the trunk and extremities, arthralgia, arthritis, myalgia, fatigue, loss of appetite with nausea and weight loss; hepatosplenomegaly and lymphadenopathy can be seen. Among laboratory examinations levels of ferritin and other acute phase reactants distinctly rise, and neutrophilic leukocytosis; ANA and RF negativity are detected. Pleural and pericardial effusions, transient pulmonary infiltration, and rarely myocarditis can be seen during the course of the disease. Here we report a patient who was examined for fever of unknown origin and diagnosed with adult onset Stills disease which is a rare etiology of pleural effusion

Covid-19 hastalarında konvelesan plazma tedavisinin etkinliği

Convalescent plasma (CP) therapy has been used for treatment, although it has not been Corona Virus 2019 Disease (COVID-19) specific antiviral agent so far. However, the effectiveness of CP treatment on prognosis and mortality is still a matter of debate. In this study, we aimed to share our experiences about the effectiveness of CP treatment in COVID-19. Patients and Methods: The study was conducted in 126 patients diagnosed with COVID-19 who received CP treatment in addition to standard treatment between May 2020 and February 2021. 126 patients were divided into two groups as those who underwent SP within the first five days (Group A) and after five days (Group B). The patients in these two groups were evaluated in terms of laboratory parameters, clinical and mortality. Results: A total of 126 patients were identified (86 patients in Group A and 40 patients in Group B). 119 (94.4%) patients were discharged with recovery, 7 (5.5%) patients died. The mean days of hospitalization were found to be 11.4±0.7 in Group A and 18.4±1.7 in Group B (p<0.001). Treatment-related lymphocyte, PLT, fibrinogen and CRP main effect of change was significant (p<0.001). However, the results were marginally significant when the two groups were compared in terms of D-dimer. When the simple effect is evaluated; Group A as not significant, while group B was significant. Starting CP treatment 5 days before or 5 days later did not change the laboratory parameters. However, D-dimer was marginally significant (p=0.058). Conclusion: In our study, it was shown that early initiation of CP treatment reduced the hospitalization, but had no effect on mortality and laboratory parameters.Corona Virüs 2019 Hastalığı (COVID-19)’nda şu ana kadar spesifik antiviral ajan olmamasına rağmen tedavi için konvelesan plazma (CP) tedavisi tedavi için kullanılmıştır. Ancak CP tedavisinin prognoz ve mortalite üzerindeki etkinliği halen tartışma konusudur. Bu çalışmada COVID-19 hastalığında CP tedavisinin etkinliğine ilişkin deneyimlerimizin paylaşması amaçlandı. Hastalar ve Yöntem: Çalışma Mayıs 2020-Şubat 2021 tarihleri arasında standart tedaviye ek olarak CP tedavisi alan 126 COVID-19 tanılı hastada gerçekleştirildi. 126 hasta ilk beş gün içinde (Grup A) ve beş günden sonra (Grup B) CP uygulananlar olarak iki gruba ayrıldı. Bu iki gruptaki hastalar laboratuvar parametreleri, klinik bulgular ve mortalite açısından değerlendirildi. Bulgular: Toplam 126 hasta Grup A'da 86 hasta ve Grup B'de 40 hasta) tespit edildi. 119 (%94.4) hasta şifa ile taburcu olurken 7 (%5,5) hasta kaybedildi. Ortalama hastane yatış süresi Grup A'da 11.4±0.7, Grup B'de 18.4±1.7 gün olarak bulundu (p<0,001). Lenfosit, PLT, fibrinojen ve CRP’nin tedaviye bağlı ana değişim etkisi istatistiksel olarak anlamlıydı (p<0.001). Ancak, iki grup D-dimer açısından karşılaştırıldığında sonuçlar marjinal olarak anlamlıydı. Basit etki değerlendirildiğinde; Grup A’daki değişim anlamlı değilken, Grup B’deki değişim anlamlıydı. CP tedavisine 5 gün önce veya 5 gün sonra başlanması laboratuvar parametrelerini değiştirmedi. Ancak, D-dimer ’daki değişim marjinal olarak anlamlıydı (p=0.058). Sonuç: Çalışmamızda CP tedavisine erken başlamanın hastanede kalış süresini azalttığı ancak mortalite ve laboratuvar parametreleri üzerine etkisinin olmadığı gösterildi